- Home
- GUTS vs ACET Comparison
GUTS vs ACET Comparison
Compare GUTS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- ACET
- Stock Information
- Founded
- GUTS 2010
- ACET 1947
- Country
- GUTS United States
- ACET United States
- Employees
- GUTS N/A
- ACET N/A
- Industry
- GUTS
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- ACET Health Care
- Exchange
- GUTS NYSE
- ACET Nasdaq
- Market Cap
- GUTS 58.8M
- ACET 64.9M
- IPO Year
- GUTS 2024
- ACET N/A
- Fundamental
- Price
- GUTS $1.60
- ACET $0.62
- Analyst Decision
- GUTS Buy
- ACET Buy
- Analyst Count
- GUTS 1
- ACET 6
- Target Price
- GUTS $10.00
- ACET $6.00
- AVG Volume (30 Days)
- GUTS 916.8K
- ACET 398.1K
- Earning Date
- GUTS 08-13-2025
- ACET 08-12-2025
- Dividend Yield
- GUTS N/A
- ACET N/A
- EPS Growth
- GUTS N/A
- ACET N/A
- EPS
- GUTS N/A
- ACET N/A
- Revenue
- GUTS $60,000.00
- ACET N/A
- Revenue This Year
- GUTS N/A
- ACET N/A
- Revenue Next Year
- GUTS N/A
- ACET N/A
- P/E Ratio
- GUTS N/A
- ACET N/A
- Revenue Growth
- GUTS N/A
- ACET N/A
- 52 Week Low
- GUTS $0.87
- ACET $0.45
- 52 Week High
- GUTS $4.92
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- GUTS 43.49
- ACET 40.64
- Support Level
- GUTS $1.54
- ACET $0.61
- Resistance Level
- GUTS $1.82
- ACET $0.69
- Average True Range (ATR)
- GUTS 0.18
- ACET 0.05
- MACD
- GUTS -0.07
- ACET -0.01
- Stochastic Oscillator
- GUTS 10.13
- ACET 6.47
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.